<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiviral agents for infectious mononucleosis (glandular fever) - De Paor, M - 2016 | Cochrane Library</title> <meta content="Antiviral agents for infectious mononucleosis (glandular fever) - De Paor, M - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011487.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiviral agents for infectious mononucleosis (glandular fever) - De Paor, M - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011487.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011487.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antiviral agents for infectious mononucleosis (glandular fever)" name="citation_title"/> <meta content="Muireann De Paor" name="citation_author"/> <meta content="RCSI Medical School" name="citation_author_institution"/> <meta content="muireanndepaor@rcsi.ie" name="citation_author_email"/> <meta content="Kirsty O'Brien" name="citation_author"/> <meta content="RCSI Medical School" name="citation_author_institution"/> <meta content="Tom Fahey" name="citation_author"/> <meta content="RCSI Medical School" name="citation_author_institution"/> <meta content="Susan M Smith" name="citation_author"/> <meta content="RCSI Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011487.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011487.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011487.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011487.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Acyclovir [adverse effects, *analogs &amp; derivatives, *therapeutic use]; Antiviral Agents [adverse effects, *therapeutic use]; Guanine [adverse effects, *analogs &amp; derivatives, therapeutic use]; Infectious Mononucleosis [*drug therapy]; Randomized Controlled Trials as Topic; Valacyclovir; Valine [adverse effects, *analogs &amp; derivatives, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011487.pub2&amp;doi=10.1002/14651858.CD011487.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011487\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011487\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","th","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011487.pub2",title:"Antiviral agents for infectious mononucleosis (glandular fever)",firstPublishedDate:"Dec 8, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011487.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011487.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011487.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011487.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011487.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011487.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011487.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011487.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011487.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011487.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15890 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011487.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/appendices#CD011487-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/table_n/CD011487StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/table_n/CD011487StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiviral agents for infectious mononucleosis (glandular fever)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#CD011487-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Muireann De Paor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#CD011487-cr-0003">Kirsty O'Brien</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#CD011487-cr-0004">Tom Fahey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information#CD011487-cr-0005">Susan M Smith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information/en#CD011487-sec-0119">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011487.pub2">https://doi.org/10.1002/14651858.CD011487.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011487-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011487-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011487-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD011487-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011487-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011487-abs-0001" lang="en"> <section id="CD011487-sec-0001"> <h3 class="title" id="CD011487-sec-0001">Background</h3> <p>Infectious mononucleosis (IM) is a clinical syndrome, usually caused by the Epstein Barr virus (EPV), characterised by lymphadenopathy, fever and sore throat. Most cases of symptomatic IM occur in older teenagers or young adults. Usually IM is a benign self‐limiting illness and requires only symptomatic treatment. However, occasionally the disease course can be complicated or prolonged and lead to decreased productivity in terms of school or work. Antiviral medications have been used to treat IM, but the use of antivirals for IM is controversial. They may be effective by preventing viral replication which helps to keep the virus inactive. However, there are no guidelines for antivirals in IM. </p> </section> <section id="CD011487-sec-0002"> <h3 class="title" id="CD011487-sec-0002">Objectives</h3> <p>To assess the effects of antiviral therapy for infectious mononucleosis (IM).</p> </section> <section id="CD011487-sec-0003"> <h3 class="title" id="CD011487-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, March 2016), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (1946 to 15 April 2016), Embase (1974 to 15 April 2016), CINAHL (1981 to 15 April 2016), LILACS (1982 to 15 April 2016) and Web of Science (1955 to 15 April 2016). We searched the World Health Organization (WHO) International Clinical Trials Registry Platform and ClinicalTrials.gov for completed and ongoing trials. </p> </section> <section id="CD011487-sec-0004"> <h3 class="title" id="CD011487-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing antivirals versus placebo or no treatment in IM. We included trials of immunocompetent participants of any age or sex with clinical and laboratory‐confirmed diagnosis of IM, who had symptoms for up to 14 days. Our primary outcomes were time to clinical recovery and adverse events and side effects of medication. Secondary outcomes included duration of abnormal clinical examination, complications, viral shedding, health‐related quality of life, days missing from school or work and economic outcomes. </p> </section> <section id="CD011487-sec-0005"> <h3 class="title" id="CD011487-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion, assessed the included studies' risk of bias and extracted data using a customised data extraction sheet. We used the GRADE criteria to rate the quality of the evidence. We pooled heterogeneous data where possible, and presented the results narratively where we could not statistically combine data. </p> </section> <section id="CD011487-sec-0006"> <h3 class="title" id="CD011487-sec-0006">Main results</h3> <p>We included seven RCTs with a total of 333 participants in our review. Three trials studied hospitalised patients, two trials were conducted in an outpatient setting, while the trial setting was unclear in two studies. Participants' ages ranged from two years to young adults. The type of antiviral, administration route, and treatment duration varied between the trials. The antivirals in the included studies were acyclovir, valomaciclovir and valacyclovir. Follow‐up varied from 20 days to six months. The diagnosis of IM was based on clinical symptoms and laboratory parameters. </p> <p>The risk of bias for all included studies was either unclear or high risk of bias. The quality of evidence was graded as very low for all outcomes and so the results should be interpreted with caution. There were statistically significant improvements in the treatment group for two of the 12 outcomes. These improvements may be of limited clinical significance. </p> <p>There was a mean reduction in 'time to clinical recovery as assessed by physician' of five days in the treatment group but with wide confidence intervals (CIs) (95% CI ‐8.04 to ‐1.08; two studies, 87 participants). Prospective studies indicate that clinical signs and symptoms may take one month or more to resolve and that fatigue may be persistent in approximately 10% of patients at six‐month follow‐up, so this may not be a clinically meaningful result. </p> <p>Trial results for the outcome 'adverse events and side effects of medication' were reported narratively in only five studies. In some reports authors were unsure whether an adverse event was related to medication or complication of disease. These results could not be pooled due to the potential for double counting results but overall, the majority of trials reporting this outcome did not find any significant difference between treatment and control groups. </p> <p>There was a mean reduction in 'duration of lymphadenopathy' of nine days (95% CI ‐11.75 to ‐6.14, two studies, 61 participants) in favour of the treatment group. </p> <p>In terms of viral shedding, the overall effect from six studies was that viral shedding was suppressed while on antiviral treatment, but this effect was not sustained when treatment stopped. </p> <p>For all other outcomes there was no statistically significant difference between antiviral treatment and control groups. </p> </section> <section id="CD011487-sec-0007"> <h3 class="title" id="CD011487-sec-0007">Authors' conclusions</h3> <p>The effectiveness of antiviral agents (acyclovir, valomaciclovir and valacyclovir) in acute IM is uncertain. The quality of the evidence is very low. The majority of included studies were at unclear or high risk of bias and so questions remain about the effectiveness of this intervention. Although two of the 12 outcomes have results that favour treatment over control, the quality of the evidence of these results is very low and may not be clinically meaningful. Alongside the lack of evidence of effectiveness, decision makers need to consider the potential adverse events and possible associated costs, and antiviral resistance. Further research in this area is warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011487-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011487-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011487-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011487-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011487-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011487-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011487-abs-0005" lang="en"> <h3>Antiviral medication for the treatment of infectious mononucleosis (glandular fever)</h3> <p><b>Review question</b> </p> <p>We investigated the benefits and side effects of antiviral treatment for people with glandular fever compared with fake treatment or standard care. </p> <p><b>Background</b> </p> <p>Glandular fever is usually caused by the Epstein Barr virus. Although not generally serious, it can lead to significant time off school or work due to intense tiredness. Rarely, it can lead to potentially life‐threatening complications. Treating people with complications is costly both in terms of healthcare costs and lost productivity. Reducing complications would benefit patient care, so it is important to identify effective treatments for people with glandular fever. </p> <p>Antiviral medications are expensive, may cause side effects and can lead to antiviral resistance. Good justification is needed to ensure best outcomes when antivirals are used. There is no agreement about whether antivirals are effective for treating people with glandular fever. </p> <p><b>Search date</b> </p> <p>April 2016.</p> <p><b>Study characteristics</b> </p> <p>We included seven studies that involved a total of 333 people; two were conducted in Europe and five in the USA. Three studies took place in hospitals, one each in a student health centre and a children's clinic, but the setting was unclear in two studies. Three different antiviral drugs were studied: acyclovir, valomaciclovir and valacyclovir, as well as dosage, comparison treatment (fake or no treatment), and how long people were treated and followed up. </p> <p><b>Study funding</b> </p> <p>One study did not report study funding, but the other six studies appeared to have some industry support. None declared conflicts of interest, but one included two authors from a drug company. </p> <p><b>Key results</b> </p> <p>We wanted to investigate several outcomes: time to recovery; medication side effects; duration of: fever, sore throat, swollen lymph nodes, enlarged spleen and liver; development of glandular fever complications; how long it took to eliminate the virus from the throat; health‐related quality of life; days off school or work; and economic outcomes. </p> <p>We found improvements in participants who received antiviral for two outcomes.</p> <p>There was an improvement of five days in time taken to recover among people who received antiviral treatment, but this result was not very precise, and the way it was measured was not clearly defined. Other studies show that glandular fever symptoms can take a month or more to get better, and tiredness may occur in about one in every 10 of patients six months later. This improvement may be of limited clinical significance. </p> <p>Most studies that examined adverse effects did not find any differences between people who received antivirals and those who did not. </p> <p>Time taken to resolve lymph node swelling improved to nine days when antivirals were used. However, studies that reported on this, measured lymph node swelling in different ways so we cannot be sure about the accuracy of the result. </p> <p><b>Quality of the evidence</b> </p> <p>Evidence quality was rated as very low for all results, which means that we cannot know the exact effect of using antivirals for glandular fever. Better studies are needed so we can draw firm conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011487-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-sec-0105">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-sec-0147">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011487-sec-0105"></div> <h3 class="title" id="CD011487-sec-0106">Implications for practice</h3> <section id="CD011487-sec-0106"> <p>The effectiveness of antiviral agents (acyclovir, valomaciclovir and valacyclovir) in acute infectious mononucleosis (IM) is uncertain. The quality of the evidence is very low; included studies were small, heterogeneous and at unclear or high risk of bias. Outcomes were selectively reported, often reported as composite scores and generally found only modest improvements which may not be clinically meaningful. Alongside the lack of evidence of effectiveness, decision makers need to consider the potential adverse events and possible associated costs, and antiviral resistance. </p> </section> <h3 class="title" id="CD011487-sec-0107">Implications for research</h3> <section id="CD011487-sec-0107"> <p>More robust clinical trials are required to further assess this research question as the quality of the current evidence is poor and based on small heterogenous studies. Most cases of symptomatic IM are encountered in young adults in a primary care environment, often in student health centres. Trials of commonly used orally‐administered antivirals versus usual care should be established in this setting. Outcomes examined should include effectiveness on acute symptoms, adverse effects, time off work or school, prevention of complications, effect of antivirals on longer‐term outcomes such as fatigue, and evaluation of economic outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011487-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011487-sec-0036"></div> <div class="table" id="CD011487-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antivirals compared with placebo/no treatment for infectious mononucleosis (glandular fever)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antivirals compared with placebo/no treatment for infectious mononucleosis (glandular fever)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)<br/> <b>Setting:</b> hospitalised patients or outpatient setting<br/> <b>Intervention:</b> antivirals<br/> <b>Comparison:</b> placebo / no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antivirals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to clinical recovery doctor judgement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery doctor judgement was 20 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery doctor judgement in the intervention group was 5 days fewer (8.04 fewer to 1.08 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant reduction in favour of treatment group. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> had 3 patients in the treatment group who had a co‐administered steroid whereas none of the placebo group had this </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to clinical recovery patient judgement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery patient judgement was 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery patient judgement in the intervention group was 6 days fewer (26.23 fewer to 15.05 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference between groups. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> had 3 patients in the treatment group who had a co‐administered steroid whereas none of the placebo group had this </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events and side effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported narratively only in five studies. In some reports authors were unsure whether adverse event was related to medication or complication of disease </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of lymphadenopathy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of lymphadenopathy was 41 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of lymphadenopathy in the intervention group was 9 days fewer (11.75 fewer to 6.14 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference in favour of treatment group. One study weighted very heavily due to high variance in other study </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of complications of Infectious mononucleosis</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three studies reported complications narratively. There did not seem to be any difference in the incidence of complications between treatment and control groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral shedding</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall effect from all six studies was that viral shedding was suppressed while on antiviral treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days missing from school / work</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days missing from school / work was 20 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days missing from school/work in the intervention group was 1 day fewer (6.53 fewer to 4.74 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference between groups. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> had 3 patients in the treatment group who had a co‐administered steroid whereas none of the placebo group had this </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for imprecision where sample size was very small (&lt; 200 participants) </p> <p><sup>2</sup> Downgraded one level for risk of bias due to the majority of studies included in this outcome having an unclear or high risk of bias </p> <p><sup>3</sup> Downgraded one level for indirectness as no study reported adverse events as a measurable outcome </p> <p><sup>4</sup> Downgraded one level for imprecision due to small sample sizes or wide confidence intervals for this outcome </p> <p><sup>5</sup> Downgraded one level for inconsistency due to wide variance of point estimates across studies and differences in setting, type of antiviral, or route of medication administration </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011487-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-sec-0127">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011487-sec-0037"></div> <p>For definitions of terminology see the Glossary of terms (<a href="./appendices#CD011487-sec-0111">Appendix 1</a>). </p> <section id="CD011487-sec-0038"> <h3 class="title" id="CD011487-sec-0038">Description of the condition</h3> <p>Infectious mononucleosis (IM) is a clinical syndrome, characterised by lymphadenopathy, fever and sore throat (<a href="./references#CD011487-bbs2-0041" title="HurtC , TammaroD . Diagnostic evaluation of mononucleosis‐like illnesses. American Journal of Medicine2007;120(10):911.e1‐8. ">Hurt 2007</a>). Ninety per cent of cases are caused by the Epstein‐Barr virus (EBV), about 5% to 7% are caused by cytomegalovirus (CMV), and less than 1% are caused by <i>Toxoplasma gondii</i> (<i>T gondii</i>) (<a href="./references#CD011487-bbs2-0036" title="EvansAS . Infectious mononucleosis and related syndromes. American Journal of the Medical Sciences1978;276(3):325‐39. ">Evans 1978</a>). EBV is a widespread virus, transmitted primarily through infected saliva. </p> <p>EBV infection may be subclinical during childhood years, without causing the overt syndrome of IM. However, the incidence of symptomatic infection rises in adolescents and adults, and studies have shown that EBV eventually infects over 95% of adults (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). The overall incidence of IM in the USA is about 500 cases per 100,000 people per year (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). In high‐income countries, the incidence of IM peaks in the late teens and falls after the age of 35 (<a href="./references#CD011487-bbs2-0024" title="AuwaerterPG . Infectious mononucleosis in middle age. Journal of the American Medical Association1999;281:454‐9. ">Auwaerter 1999</a>). In contrast, in low‐income countries most children are infected with EBV before they reach adolescence and symptomatic IM is uncommon (<a href="./references#CD011487-bbs2-0056" title="StrausSE , CohenJI , TosatoG , MeierJ . Epstein‐Barr virus infections: biology, pathogenesis, and management. Annals of Internal Medicine1993;118:45‐58. ">Straus 1993</a>). </p> <p>Following infection with EBV, the incubation period is four to eight weeks (<a href="./references#CD011487-bbs2-0012" title="EbellMH . Eipstein‐Barr virus infectious mononucleosis. American Family Physician2004;70:1279‐87. ">Ebell 2004</a>). Symptoms of IM usually peak one week from onset, and generally start to resolve over the next one to four weeks (<a href="./references#CD011487-bbs2-0051" title="MacsweenKF , HigginsCD , McAulayKA , WilliamsH , HarrisonN , SwerdlowAJ , et al. Infectious mononucleosis in university students in the United Kingdom: evaluation of the clinical features and consequences of the disease. Clinical Infectious Diseases2010;50(5):699‐706. ">Macsween 2010</a>; <a href="./references#CD011487-bbs2-0053" title="ReaTD , RussoJE , KatonW , AshleyRL , BuchwaldDS . Prospective study of the natural history of infectious mononucleosis caused by Epstein‐Barr virus. Journal of the American Board of Family Practice / American Board of Family Practice2001;14:234‐42. ">Rea 2001</a>). Occasionally, fatigue after acute IM can be severe and persistent. Persistent fatigue was present in 12% of cases at six months after illness onset in one prospective study (<a href="./references#CD011487-bbs2-0029" title="BuchwaldDS , ReaTD , KatonWJ , RussoJE , AshleyRL . Acute infectious mononucleosis: characteristics of patients who report failure to recover. American Journal of Medicine2000;109:531‐7. ">Buchwald 2000</a>), and another cohort study found that 9% to 22% of patients with IM were classified as having Chronic Fatigue Syndrome six months after the acute illness (<a href="./references#CD011487-bbs2-0059" title="WhitePD , ThomasJM , KangroHO , Bruce‐JonesWD , AmessJ , CrawfordDH , et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet2001;358(9297):1946‐54. ">White 2001</a>). The virus can continue to shed in saliva for a median duration of six months (<a href="./references#CD011487-bbs2-0027" title="BalfourHHJr , OdumadeOA , SchmelingDO , MullanBD , EdJA , KnightJA , et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein‐Barr virus infection in university students. Journal of Infectious Diseases2013;207(1):80‐8. ">Balfour 2013</a>). </p> <p>IM is regarded as a benign disease in the majority of cases and is associated with typical features of fever, pharyngitis, lymphadenopathy, fatigue and atypical lymphocytosis (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). </p> <p>IM is usually diagnosed clinically, based on characteristic signs and symptoms. Typical features of IM include lymphadenopathy, fever, sore throat and fatigue. However, there are no definitive diagnostic criteria. Blood testing during acute IM also usually reveals (atypical) lymphocytosis and abnormal liver function tests (LFTs) (<a href="./references#CD011487-bbs2-0031" title="CharlesPGP . Infectious mononucleosis. Australian Family Physician2003;32:785‐8. ">Charles 2003</a>). Laboratory tests are usually not required for diagnosis. However, specific antibody tests may be required to confirm diagnosis or to identify the cause of illness in atypical cases. A definitive diagnosis can be made by testing for IgG and IgM antibodies against viral capsid antigens, early antigens and EBV nuclear antigen proteins (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). Recent studies have proposed a number of biomarkers for monitoring disease severity in IM caused by EBV (<a href="./references#CD011487-bbs2-0043" title="KawanoY , IwataS , KawadaJ , GotohK , SuzukiM , ToriiY , et al. Plasma viral microRNA profiles reveal potential biomarkers for chronic active Epstein‐Barr virus infection. Journal of Infectious Diseases2013;208:771‐9. ">Kawano 2013</a>; <a href="./references#CD011487-bbs2-0057" title="van deVeerdonkFL , WeverPC , HermansMH , FijnheerR , JoostenLA , van derMeerJW , et al. IL‐18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity. Journal of Infectious Diseases2012;206:197‐201. ">van de Veerdonk 2012</a>). </p> <p>IM can be associated with a variety of complications affecting multiple organ systems. As previously mentioned, fatigue after IM can be prolonged. Haematological complications are observed in 25% to 50% of cases and are generally mild (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). Rare complications, such as airway occlusion secondary to oedema of the soft palate and tonsils and peritonsillar abscess, can occur (<a href="./references#CD011487-bbs2-0052" title="MonemSA , O'ConnorPF , O'LearyTG . Peritonsillar abscess and infectious mononucleosis: an association or a different presentation of the same condition. Irish Medical Journal1999;92(2):278‐80. ">Monem 1999</a>). Upper airway obstruction is seen in approximately 1% of cases (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). Splenomegaly is seen in approximately 50% of patients with IM, but usually begins to resolve by the third week of the illness (<a href="./references#CD011487-bbs2-0030" title="CarterRL , PenmanHG . Infectious Mononucleosis. Oxford and Edinburgh: Blackwell Scientific Publication, 1969. ">Carter 1969</a>). Splenic rupture is rare ‐ occurring in 0.1% to 0.2% of cases (<a href="./references#CD011487-bbs2-0021" title="AldreteJS . Spontaneous rupture of the spleen in patients with infectious mononucleosis. Mayo Clinic Proceedings1992;67:910‐2. ">Aldrete 1992</a>) ‐ but potentially fatal (<a href="./references#CD011487-bbs2-0028" title="BrichkovI , CummingsL , FazylovR , HorovitzJH . Nonoperative management of spontaneous splenic rupture in infectious mononucleosis: the role for emerging diagnostic and treatment modalities. American Journal of Surgery2006;72(5):401‐4. ">Brichkov 2006</a>). EBV has also been associated with other complications including pneumonia, pleural effusions (<a href="./references#CD011487-bbs2-0032" title="ChenJ , KonstantinopoulosPA , SatyalS , TelonisJ , BlairDC . Just another simple case of infectious mononucleosis?. Lancet2003;361(9364):1182. ">Chen 2003</a>), hepatitis (<a href="./references#CD011487-bbs2-0033" title="DevereauxCE , BemillerT , BrannO . Ascites and severe hepatitis complicating Epstein‐Barr infection. American Journal of Gastroenterology1999;94(1):236‐40. ">Devereaux 1999</a>) and cholestasis, myocarditis and cardiac conduction abnormalities, acute renal failure (<a href="./references#CD011487-bbs2-0047" title="LeiPS , LowichikA , AllenW , MauchTJ . Acute renal failure: unusual complication of Epstein‐Barr virus‐induced infectious mononucleosis. Clinical Infectious Diseases2000;31(6):1519‐24. ">Lei 2000</a>), and in 1% to 5% of cases, neurological complications (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). </p> <p>IM is generally self‐limiting, and there is no specific treatment. The mainstay of treatment for IM is supportive care. Patients should be encouraged to maintain adequate fluid and nutrition intake. Over‐the‐counter medications are recommended to relieve symptoms of sore throat, fever and malaise (<a href="./references#CD011487-bbs2-0050" title="LuzuriagaK , SullivanJL . Infectious mononucleosis. New England Journal of Medicine2010;362(21):1993‐2000. ">Luzuriaga 2010</a>). Corticosteroids may be used in the treatment of complications. However, a Cochrane review evaluating the effectiveness of corticosteroids for the control of symptoms concluded that there was insufficient evidence of clinical benefit (<a href="./references#CD011487-bbs2-0055" title="RezkE , NofalYH , HamzehA , AboujaibMF , AlKhederMA , Al HammadMF . Steroids for symptom control in infectious mononucleosis. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD004402.pub3] ">Rezk 2015</a>). Metronidazole, an anaerobic antibacterial agent, has recently been studied in severe cases of patients with IM who were hospitalised and found to reduce length of hospital stay <a href="./references#CD011487-bbs2-0048" title="LennonP , O'NeillJP , FentonJE . Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial. Clinical Microbiology and Infection2014;20(7):45‐2. ">Lennon 2014</a>. Antiviral medications have been used to treat IM, but the use of antivirals for IM is controversial. </p> </section> <section id="CD011487-sec-0039"> <h3 class="title" id="CD011487-sec-0039">Description of the intervention</h3> <p>Antivirals for IM have been studied previously in a 1999 meta‐analysis of five randomised controlled trials (RCTs) of acyclovir for the treatment of IM (<a href="./references#CD011487-bbs2-0017" title="TorreD , TambiniR . Acyclovir for treatment of infectious mononucleosis: a meta‐analysis. Scandinavian Journal of Infectious Diseases1999;31:543‐7. ">Torre 1999</a>). This systematic review showed less oropharyngeal EBV shedding at the end of therapy but failed to show a clinical benefit in terms of pharyngitis, weight loss and absence from school or work compared to placebo. A randomised pilot study comparing valacyclovir with no treatment in young adults with IM showed a transient reduction of oropharyngeal EBV shedding during therapy and a decrease in the number and severity of reported symptoms in the valacyclovir group, but with no difference between the two groups in the peripheral blood EBV load (<a href="./references#CD011487-bbs2-0026" title="BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39(1):16‐21. ">Balfour 2007</a>). </p> </section> <section id="CD011487-sec-0040"> <h3 class="title" id="CD011487-sec-0040">How the intervention might work</h3> <p>There are several antiviral agents, but the two that have been studied most with respect to IM are acyclovir and valacyclovir. Acyclovir is a nucleoside analogue that selectively inhibits the replication of certain viruses. It is active against herpes simplex virus types 1 and 2 (HSV‐1, HSV‐2), varicella zoster virus (VZV) and EBV. Valacyclovir acts as an oral prodrug and is converted in vivo to acyclovir. Other antiviral agents that have been shown to have in vitro activity against herpes viruses are penciclovir, famciclovir, ganciclovir, valganciclovir, cidofovir and foscarnet (<a href="./references#CD011487-bbs2-0044" title="KimberlinDW , WhitleyRJ . Chapter 64: Antiviral therapy of HSV‐1 and ‐2. In: ArvinA , Campadelli‐FiumeG , MocarskiE , et al. editor(s). Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007. ">Kimberlin 2007</a>). All these agents act by preventing viral replication by inhibiting viral DNA synthesis. This helps to keep the virus inactive. </p> <p>Antiviral medications are generally well tolerated. However, the most commonly reported side effects of acyclovir (observed in between 1/10 and 1/100 of cases) are nausea, vomiting, diarrhoea and abdominal pain, headache, dizziness, fatigue and fever, as well as skin rashes (including photosensitivity and itching) (<a href="./references#CD011487-bbs2-0040" title="Health Products Regulatory Authority (HPRA) Ireland. NA [NA]. NA Accessed 19 May 2015; Vol. NA, issue NA:NA. ">HPRA 2016</a>). </p> </section> <section id="CD011487-sec-0041"> <h3 class="title" id="CD011487-sec-0041">Why it is important to do this review</h3> <p>IM is a commonly encountered illness in primary care settings. A general practice with 10,000 patients can expect to see approximately seven new cases of IM a year (<a href="./references#CD011487-bbs2-0010" title="CandyB , ChalderT , CleareAJ , WesselyS , WhitePD , HotopfM . Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. British Journal of General Practice2002;52:844‐51. ">Candy 2002</a>). Although generally not considered a serious illness, IM can lead to significant loss of time from school or work due to profound fatigue (<a href="./references#CD011487-bbs2-0051" title="MacsweenKF , HigginsCD , McAulayKA , WilliamsH , HarrisonN , SwerdlowAJ , et al. Infectious mononucleosis in university students in the United Kingdom: evaluation of the clinical features and consequences of the disease. Clinical Infectious Diseases2010;50(5):699‐706. ">Macsween 2010</a>), or the development of chronic illness (<a href="./references#CD011487-bbs2-0010" title="CandyB , ChalderT , CleareAJ , WesselyS , WhitePD , HotopfM . Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. British Journal of General Practice2002;52:844‐51. ">Candy 2002</a>). Also, in rare cases, it can lead to potentially life‐threatening complications such as splenic rupture, encephalitis and severe upper airway obstruction (<a href="./references#CD011487-bbs2-0042" title="JensonHB . Acute complications of Epstein‐Barr virus infectious mononucleosis. Current Opinion in Pediatrics2000;12(3):263‐8. ">Jenson 2000</a>). If the incidence of complications could be reduced, by implementing evidence‐based treatment, it would impact positively on patient care. These complications also have economic implications ‐ both in terms of healthcare costs and loss of productivity. As such, there is great interest in developing regimens for treating IM with antiviral agents. </p> <p>Antiviral medications are known to be expensive. Another consideration is the emergence of resistance to antiviral agents. There needs to be an evidence base for using these medications so that the available resources are used efficiently and effectively. To our knowledge, there are no professional society guidelines for the management of IM. This indicates a lack of clarity regarding the current evidence in relation to antiviral treatment for IM. It is hoped that the findings of this review will inform the preparation of a clinical guideline or policy document. </p> <p>The previous meta‐analysis examining acyclovir for the treatment of IM showed some benefit in reducing oropharyngeal EBV shedding but no evidence to support its clinical effectiveness (<a href="./references#CD011487-bbs2-0017" title="TorreD , TambiniR . Acyclovir for treatment of infectious mononucleosis: a meta‐analysis. Scandinavian Journal of Infectious Diseases1999;31:543‐7. ">Torre 1999</a>). These data are now 15 years old and only included one antiviral agent, acyclovir. We feel it is necessary to search, appraise and summarise RCTs of antiviral agents for IM. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011487-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-sec-0132">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011487-sec-0042"></div> <p>To assess the effects of antiviral therapy for infectious mononucleosis (IM).</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011487-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-sec-0133">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011487-sec-0043"></div> <section id="CD011487-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011487-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) that examine the benefits and side effects of antiviral medication in infectious mononucleosis (IM). </p> </section> <section id="CD011487-sec-0046"> <h4 class="title">Types of participants</h4> <p>Immunocompetent participants of any age or sex with both clinical and laboratory‐confirmed diagnosis of IM, who had symptoms for up to 14 days. Laboratory diagnosis is by monospot test or atypical lymphocytosis or EBV‐specific serology. </p> </section> <section id="CD011487-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Antiviral medication (acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, valganciclovir, cidofovir and foscarnet) used for any duration or at any dose or by any route of administration. We included RCTs comparing antivirals with placebo or no treatment. </p> </section> <section id="CD011487-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD011487-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011487-list-0001"> <li> <p>Time to clinical recovery.</p> </li> <li> <p>Adverse events and side effects of medication: as reported in the original studies by patients and clinicians. </p> </li> </ol> </p> </section> <section id="CD011487-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011487-list-0002"> <li> <p>Duration of abnormal clinical examination (as assessed clinically by physician). We included: </p> <ol id="CD011487-list-0003"> <li> <p>fever (&gt; 37.5° C);</p> </li> <li> <p>pharyngitis;</p> </li> <li> <p>lymphadenopathy;</p> </li> <li> <p>splenomegaly;</p> </li> <li> <p>hepatomegaly.</p> </li> </ol> </li> <li> <p>Development of complications of IM.</p> </li> <li> <p>Viral shedding (as reported in the original studies).</p> </li> <li> <p>Patient‐reported outcome measures:</p> <ol id="CD011487-list-0004"> <li> <p>health‐related quality of life (as reported in the original studies);</p> </li> <li> <p>days missing from school or work.</p> </li> </ol> </li> <li> <p>Economic outcomes: based on collecting cost data from studies, where available.</p> </li> </ol> </p> </section> </section> </section> <section id="CD011487-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>See <a href="#CD011487-fig-0001">Figure 1</a> for study flow diagram. </p> <div class="figure" id="CD011487-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011487-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD011487-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, March 2016), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (1946 to 15 April 2016), Embase (1974 to 15 April 2016), CINAHL (1981 to 15 April 2016), LILACS (1982 to 15 April 2016) and Web of Science (1955 to 15 April 2016). We used the search strategy in <a href="./appendices#CD011487-sec-0112">Appendix 2</a> to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (<a href="./references#CD011487-bbs2-0046" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org2011. ">Lefebvre 2011</a>). We adapted the search strategy to search the other databases. We imposed no language, publication date or publication status restrictions on the electronic database searches. </p> </section> <section id="CD011487-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>) and <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> for completed and ongoing trials. We checked the reference lists of included trials to ensure that the main search has not missed any trials. We contacted the authors of included trials that were published in the last 10 years for the purpose of identifying missing trials. We contacted the European Medicines Agency (EMA) to ask for clinical study reports for any relevant trials. </p> </section> </section> <section id="CD011487-sec-0054"> <h3 class="title" id="CD011487-sec-0054">Data collection and analysis</h3> <section id="CD011487-sec-0055"> <h4 class="title">Selection of studies</h4> <p>We retrieved all titles and abstracts to assess eligibility against the inclusion criteria, as well as to identify multiple reports from single studies. We obtained full text copies of all papers considered to be potentially eligible and two review authors (MDP, SS) independently assessed these for suitability for inclusion. We resolved any disagreement by discussion between pairs of review authors, and where necessary, a third review author. We contacted the authors of a number of the primary studies for clarification. We excluded any papers that did not meet the inclusion criteria. </p> </section> <section id="CD011487-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MDP, KOB) independently completed data extraction using a standard data extraction form. The pair of review authors and, where necessary, a third review author, resolved any disagreement by discussion. </p> </section> <section id="CD011487-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>A combination of two authors (MDP, KOB) assessed risk of bias using the tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011487-bbs2-0038" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.handbook.cochrane.org2011. ">Higgins 2011</a>). We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD011487-list-0005"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other bias (other sources of bias related to particular trial design (cross‐over and cluster‐randomised) or specific circumstances). </p> </li> </ol> </p> <p>We classified the risk of bias as: low risk, high risk or unclear risk of bias (<a href="./references#CD011487-bbs2-0038" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.handbook.cochrane.org2011. ">Higgins 2011</a>). We completed an overall 'Risk of bias' assessment graph displaying the review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> <p>Where necessary, we contacted study authors for clarification. We resolved any disagreement by discussion between the two review authors and, where necessary, a third review author. </p> </section> <section id="CD011487-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We measured treatment effect by using either dichotomous data or an ordinal rating scale. For continuous data, we calculated the mean difference (MD) (using the method described in <a href="./references#CD011487-bbs2-0039" title="HozoS P , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 20 April 2005;5:13. ">Hozo 2005</a>). We planned to use the standardised mean difference (SMD) if different measures had been used. Where results were reported as mean and standard error, standard deviations were calculated as per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011487-bbs2-0038" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.handbook.cochrane.org2011. ">Higgins 2011</a>) by multiplying the standard error of a mean by the square root of the sample size. </p> </section> <section id="CD011487-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We considered the individual the unit of analysis. If we had identified any non‐standard design RCTs, we planned to follow the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011487-bbs2-0038" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.handbook.cochrane.org2011. ">Higgins 2011</a>). </p> </section> <section id="CD011487-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We contacted lead study investigators or corresponding authors for missing trial data, along with data missing from published reports and for additional clarification. Three authors responded with additional information but only one was in a position to provide selected original data. </p> <p>For data reported as median and range, we used the method described in <a href="./references#CD011487-bbs2-0039" title="HozoS P , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 20 April 2005;5:13. ">Hozo 2005</a> to convert it to mean and standard deviation. Where there were data missing from a study, we have explicitly stated this and reported it in the 'Risk of Bias' table. We have commented on the potential impact of missing data on the review findings in the <a href="#CD011487-sec-0099">Discussion</a>. </p> </section> <section id="CD011487-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed included studies for clinical heterogeneity. We pooled minimal data for analysis across trials as we found diversity in the intervention (which drug was administered, route of administration, co‐administered medication, use of placebo), outcomes (which outcomes were reported at which time points and whether they were continuous or dichotomous outcomes), and length of follow‐up. </p> </section> <section id="CD011487-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to minimise reporting bias by conducting a comprehensive search for studies that met the eligibility criteria, including grey literature and unpublished trials, and by contacting trial authors for missing information. We planned to assess the potential for publication bias in funnel plot analysis if we had sufficient and appropriate trial data to combine. </p> </section> <section id="CD011487-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We had intended to perform a meta‐analysis to calculate a weighted intervention effect for our primary outcome across trials. However, we found that the trial outcomes were too heterogeneous. We pooled the results of some of the studies where appropriate. We performed the statistical analyses using Review Manager software (<a href="./references#CD011487-bbs2-0054" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We prepared a 'Summary of findings' table to present the results for five of the outcomes, including adverse effects, as outlined in the <a href="#CD011487-sec-0048">Types of outcome measures</a> section (with results synthesised mainly narratively). We used the five GRADE (<a href="./references#CD011487-bbs2-0023" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes. The GRADE approach specifies four levels of quality. The highest quality rating is for randomised trial evidence. However, randomised trial evidence may be downgraded to moderate, low or even very low quality evidence, depending on the presence of the above five considerations (<a href="./references#CD011487-bbs2-0038" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.handbook.cochrane.org2011. ">Higgins 2011</a>). We used the GRADEproGDT software to prepare the table (<a href="./references#CD011487-bbs2-0037" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). We justified all decisions to down‐ or up‐grade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary. </p> </section> <section id="CD011487-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to pursue subgroup analyses based on patient age, setting and placebo versus no treatment controls with sufficient data but unfortunately this was not possible. </p> </section> <section id="CD011487-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to carry out a sensitivity analysis to explore the impact of risk of bias on study findings but all included studies were at a moderate or high risk of bias, so this was not possible. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011487-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011487-sec-0066"></div> <section id="CD011487-sec-0067"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011487-sec-0125" title="">Characteristics of included studies</a> and <a href="./references#CD011487-sec-0126" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD011487-sec-0068"> <h4 class="title">Results of the search</h4> <p>We obtained a total of 1691 abstracts from electronic searches. We found an additional 22 studies from searching other sources. From the screening of titles and abstracts, we found 22 studies to be potentially relevant. On full‐text retrieval, we excluded 13 studies leaving nine to be analysed. Three (<a href="./references#CD011487-bbs2-0022" title="AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ">Andersson 1985</a>; <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0035" title="ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Ernberg 1986</a>) appear to be different reports of the same study. We tried to contact the trial authors for confirmation of this but did not receive any response. We used <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> as the main paper for this trial, thus leaving us with seven included studies. </p> </section> <section id="CD011487-sec-0069"> <h4 class="title">Included studies</h4> <p>We included seven trials (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>; <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>; <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>; <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>; <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>) and summarised them in the <a href="./references#CD011487-sec-0125" title="">Characteristics of included studies</a> table. </p> <section id="CD011487-sec-0070"> <h5 class="title">Intervention</h5> <p>Six of the seven studies explored the effects of antivirals versus placebo and one trial compared antiviral treatment with no drug (<a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>). The antivirals examined were acyclovir, valomaciclovir and valacyclovir. One of the trials had a third study arm which compared antiviral and steroid versus placebo (<a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>). </p> <p>The dose of antiviral, route of administration, and duration of treatment varied between the trials. </p> <p>In <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>, three patients in the treatment group required intravenous (IV) antiviral and steroid for 10 days, whereas none of the patients in the placebo group had this treatment. In <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>, 11 of 15 in the treatment group and nine of 16 in the placebo group had antibiotics pre admission. In <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>, some participants had oral steroids co‐administered, but it is not reported how many from each group had this. In <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>, two patients in the placebo group and one in the treatment group had steroids co‐administered. </p> </section> <section id="CD011487-sec-0071"> <h5 class="title">Setting</h5> <p>Two of the studies were conducted in Europe (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>), while the other five took place in the USA. The European trials along with <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a> took place in an inpatient setting. <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> and <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> took place in outpatient settings, with <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> set in a student health centre and <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> in a paediatric clinic. The trial setting was unclear in two of the studies (<a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>; <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>). All trials were undertaken by researchers either located in hospitals or at academic institutions. </p> </section> <section id="CD011487-sec-0072"> <h5 class="title">Participants</h5> <p>Participants ranged in age from young children (aged from two) to young adults (although no maximum age was specified in the exclusion criteria of most of the trials). Four trials mentioned a maximum age: 25 years in <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; 30 years in <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; 24 years in <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>; and 18 years in <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>. <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> reported median ages of 19.3 years in the treatment group and 21.4 in the control group. <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a> reported a mean age of 19.5 years in the treatment group and a mean age of 21 years in the placebo group. <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> did not report the age of participants. In the six trials that reported gender, there were consistently more males than females. One trial did not report the participants' ages (<a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>). One trial did not report the gender of participants (<a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>), One of the inclusion criteria for this review were that diagnosis of infectious mononucleosis (IM) was based on clinical symptoms and laboratory parameters. The laboratory tests used in the studies included positive heterophile test, monospot test, atypical lymphocytosis, and antibody testing. Our inclusion criteria also specified that symptoms should be present for 14 days or less and that participants should be immunocompetent. In <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>, the duration of symptoms and immunocompetence of the participants was unclear. The average time from symptom onset to trial inclusion was variably reported; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported the time from clinical onset to treatment but it was unclear whether this was trial treatment or otherwise, <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> reported number of days with symptoms before admission but again it was unclear as to whether admission referred to trial inclusion or hospitalisation; <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> and <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> reported number of days ill at baseline. </p> </section> <section id="CD011487-sec-0073"> <h5 class="title">Outcomes and follow‐up assessment</h5> <p>Outcomes examined to evaluate the effectiveness of antivirals were quite heterogenous between studies. </p> <p>One of our primary outcomes ‐ time to clinical recovery ‐ was reported as the number of days in two studies (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>). <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> also reported the outcome in a dichotomous way; as recovery by day five or 10. </p> <p>Adverse events and side effects of medication (which was the other primary outcome) were reported narratively in five trials (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>; <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>; <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>). </p> <p>Viral shedding was the most evaluated outcome, reported by six trials. Other outcomes reported by more than one study included: duration of abnormal clinical examination (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>), development of complications (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>), days missing from school or work (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>). </p> <p>Outcomes were assessed at different times in the different studies. The length of follow‐up was not clear from some of the studies and it was inferred from information in the results tables, etc. Follow‐up varied from 20 days (<a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>), 35 days (<a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>), 120 days (<a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>), 170 days (<a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>) to six months (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>). </p> </section> </section> <section id="CD011487-sec-0074"> <h4 class="title">Excluded studies</h4> <p>Studies were excluded for a variety of reasons based on study design and intervention criteria. Full descriptions of such exclusions are detailed in the <a href="./references#CD011487-sec-0126" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD011487-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>All seven included studies were at either unclear or high risk of bias (see <a href="./references#CD011487-sec-0125" title="">Characteristics of included studies</a> table). The 'Risk of bias' summary and 'Risk of bias' graph are presented in <a href="#CD011487-fig-0002">Figure 2</a> and <a href="#CD011487-fig-0003">Figure 3</a>, respectively. </p> <div class="figure" id="CD011487-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011487-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011487-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011487-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011487-sec-0076"> <h4 class="title">Allocation</h4> <p>Three trials provided adequate details on allocation concealment (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>); in the remaining four trials this was unclear (<a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>; <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>; <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>; <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>). </p> </section> <section id="CD011487-sec-0077"> <h4 class="title">Blinding</h4> <p>Five of the trials were 'double‐blinded' but did not specify who was blinded (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>; <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>; <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>). In <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> details were found on clinicaltrials.gov specifying that participant, caregiver, investigator and outcomes assessor were blinded. In <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> clinical observers and participants were not blinded. </p> </section> <section id="CD011487-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>In four trials there was a high risk of attrition bias (<a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>; <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>; <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>; <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>), and in the remaining three trials there was an unclear risk of attrition bias (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>; <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>). </p> </section> <section id="CD011487-sec-0079"> <h4 class="title">Selective reporting</h4> <p>The risk of selective reporting in all included trials was high. For <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>, the outcome difficulty with swallowing was stated in the methods section but not reported in the results section. Similarly in <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>, lymphadenopathy was not reported although it states in the methods section that it was measured at visits. In <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>, clinical examination or symptom scores were not individually reported, but were reported as a composite score of 10 parameters. This was also the case in <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>; individual symptom scores were not all reported, but only reported as composite scores. In <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>, clinic visits took place on days 5, 10, 15, 18, 21, 42, 84, and 168, but clinical data were only reported up to day 15. Clinical outcomes were not fully reported for <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>; only reported narratively with no actual results given. In <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>, it was stated that some of the outcomes were measured on days 3, 5, 10, and 30, but these were only reported in baseline data. </p> </section> <section id="CD011487-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>In the trial <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>, some patients received IV fluids, some also had antibiotics before the trial. In the trial <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>, there were differences in the severity of illness between patients and three patients who had IV rather than oral antiviral and steroids were included in the analysis. In <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a>, some participants had oral steroids co‐administered, but it is not reported how many from each group had this. <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> is an unpublished trial, and therefore not peer reviewed. In <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a>, it was unclear whether patients had symptoms for 14 days or less. Two patients in the placebo group and one in the treatment group had steroids. The groups in the trial <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> had significant baseline imbalances in that more acyclovir recipients had a temperature &gt; 37.5°C, and the mean pharyngitis score was slightly greater for acyclovir recipients. </p> <p>Most of the studies appeared to have industry funding. <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> were both supported by the Wellcome foundation. <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> was supported by an investigator‐initiated grant from Epiphany Biosciences. <a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> was supported by grants including an investigator‐initiated grant from Roche Laboratorie. <a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a> and <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> were both supported by a grant from Burroughs‐Wellcome company. In <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>, the study funding source and conflicts of interest were not stated. However, two of the authors were from a drug company. </p> </section> </section> <section id="CD011487-sec-0081"> <h3 class="title" id="CD011487-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD011487-tbl-0001"><b>Summary of findings for the main comparison</b> Antivirals compared with placebo/no treatment for infectious mononucleosis (glandular fever)</a> </p> <p>We included seven randomised controlled trials (RCTs) with a total of 333 participants in the review. The trials dated from 1983 to 2007 and were heterogeneous in terms of outcome assessment and how they were reported, therefore few trial results were pooled. There were statistically significant improvements in the treatment group for two of 12 outcomes. The quality of evidence was graded as very low for all outcomes See <a href="./full#CD011487-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD011487-sec-0082"> <h4 class="title">Primary outcomes</h4> <section id="CD011487-sec-0083"> <h5 class="title">1. Time to clinical recovery</h5> <p>Six of the seven included studies reported time to clinical recovery but reported this in different formats. When the two trials (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>) that reported this homogenously were pooled, there was an overall statistically significant reduction in favour of treatment group for this outcome as measured by physician but not by patient assessment. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported the time to clinical recovery as a continuous outcome and subdivided this into 'patient assessment' and 'physician assessment'. It should be noted that in <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> three patients in the treatment group had a co‐administered steroid, whereas none of the placebo group had this. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> reported a statistically significant reduction in time to clinical recovery as assessed by physician of five days (95% CI ‐8.21 to ‐0.79) in favour of the treatment group. This study also reported a non statistically significant reduction in time to clinical recovery as assessed by patient of 18 days (95% CI ‐44.23 to 7.23) in favour of the treatment group. </p> <p><a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported a non statistically significant reduction in time to clinical recovery as assessed by physician of five days (95% CI ‐14.97 to 4.97) in favour of the treatment group. This study also reported a non statistically significant reduction in time to clinical recovery as assessed by patient of three days (95% CI ‐14.48 to 20.48) in favour of the control group. </p> <p>When the results of <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> were pooled for 'time to clinical recovery as assessed by physician' there was a statistically significant mean reduction of five days in the treatment group but with wide confidence intervals (95% CI ‐8.04 to ‐1.08, 87 participants) (<a href="./references#CD011487-fig-0004" title="">Analysis 1.1</a>). Pooling the results of <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> for the outcome 'time to clinical recovery as assessed by patient' did not yield any statistically significant result (<a href="./references#CD011487-fig-0005" title="">Analysis 1.2</a>). The result for this analysis was a reduction of six days (95% CI ‐26.23 to 15.05, 87 participants) in favour of the treatment group. </p> <p><a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> reported this as a dichotomous outcome at two time points; the number of participants with recovery or not by day five, or day 10. There was a non statistically significant risk ratio of 1.74 (95% CI 0.69 to 4.41) in favour of a higher proportion of participants recovered in the treatment group at day five. There was a non statistically significant risk ratio of 1.10 (95% CI 0.74 to 1.64) in favour of a higher proportion of participants recovered in the treatment group at day 10. </p> <p><a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> reported the SF12 (<a href="./references#CD011487-bbs2-0058" title="WareJJr , KosinskiM , KellerSD . A 12‐Item Short‐Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical Care1996;34(3):220‐33. ">Ware 1996</a>) composite score at days one and 28 and determined the amount of change from the baseline for each group. It was not possible to access the original data to assess these outcomes individually. In the SF12; Physical and Mental Health Composite Scores (PCS &amp; MCS) are calculated using the scores of 12 questions and range from zero to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health. The median change from baseline at day 28 in the treatment group in this study was +17.1, whereas the median change from baseline in the control group was +11.2 indicating that there was a difference of 5.9 points in favour of the treatment group. Given that this score ranges from zero to 100, this is likely to be a modest clinical improvement in the antiviral group. The authors did not report ranges or standard deviation for these results, but did report that the differences were not statistically significant. </p> <p><a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> reported a composite score; 'Severity of Illness Score', which was developed by the authors and described in a previous study (<a href="./references#CD011487-bbs2-0025" title="BalfourHHJr , HolmanCJ  , HokansonKM  , LelonekMM  , GiesbrechtJE  , WhiteDR  , et al. A prospective clinical study of Epstein‐Barr virus and host interactions during acute infectious mononucleosis. Journal of Infectious Diseases2005;192:1505‐12. ">Balfour 2005</a>). It was not possible to access the original data to assess these outcomes individually. The severity of illness score is the sum of the evaluations of physical activity limitation and symptom or pain intensity. Scores range from zero (completely asymptomatic) to six (severely affected). The median 'severity of illness score' for each group was reported graphically at study enrolment, day five, day 10, day 15 and day 20, but a range was only reported for the day‐15 result. At day 15, the median score was 1 in the treatment group, and 2 in the control group. This meant that there was a statistically significant mean difference (MD) of ‐1.00 (95% CI ‐1.82 to ‐0.18) in favour of the treatment group at this time point. </p> <p><a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> reported composite scores (which were developed by the authors) at certain time points but it was not possible to access the original data to assess these outcomes individually. Four scoring systems were developed by the authors: 'total score' (composite score incorporating sore throat, stomach ache, fatigue, swollen glands, headache, vomiting, rash, nausea, sweats, chills, swollen eyes, runny nose, cough); 'selected score' (composite score incorporating sore throat, fatigue, swollen glands, nausea and chills); 'feeling bad' and 'fatigue'. Results were reported for these four outcomes in terms of 'analysis of change from baseline scores at day 20'. We felt that 'total score' was the outcome likely to equate most closely with recovery. Unfortunately, it was not clear what the maximum value for 'total score' was, but a higher score indicated that a participant was more unwell. The highest average (unclear whether this was mean or median) 'total score' at baseline in the treatment group was 10.7, and 8.7 in the control group. There was a non statistically significant mean difference in change from baseline of 'total score' at day 20 of ‐4.46 (95% CI ‐9.02 to 0.10) in favour of the treatment group. </p> <p><a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a> did not report this outcome; there was a summary given of the clinical outcome results but no clinical data reported in the paper. </p> </section> <section id="CD011487-sec-0084"> <h5 class="title">2. Adverse events and side effects of medication</h5> <p>Five of the seven studies reported adverse events of medication narratively and the majority reported no significant difference between groups for this outcome. It was not possible to pool the results for this outcome because of the potential for double counting results. Trial participants may have had more than one adverse outcome and this was not clear in the reporting of the original studies. </p> <p><a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> reported that no adverse events were observed. </p> <p><a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> reported that there was no difference between the two treatment groups in terms of side effects despite the large dose of acyclovir given. It was also reported in this study that “Ten acyclovir recipients had a rising SGOT or SGPT level on day 10 or 30 compared with 15 placebo recipients. All abnormalities resolved.” </p> <p><a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> listed the adverse events in a summary format: abdominal pain, headache, nausea, vomiting, rash. Of these; nausea was the only symptom where a statistically significant difference was observed between the two treatment groups with seven participants in the treatment group and one patient in the placebo group affected (P value 0.03). One serious adverse event was reported ‐ a case of pancreatitis but the authors stated that this was more likely to be a complication of IM rather than a side effect of medication. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> reported that an asymptomatic, transient elevation of serum creatinine and urea was noted in two patients from the treatment group and in none in the placebo group. Thrombophlebitis was found in four patients from both treatment groups. Skin rashes were found in three of the patients treated with antiviral, but these patients were also treated with ampicillin pre‐admission) and six patients from the placebo group (of whom four were given ampicillin pre‐admission). During the six‐month follow‐up, a total of 12 cases of upper respiratory tract infection or tonsillitis were noted. Ten of the 12 were diagnosed as bacterial complications, and were evenly distributed in the two groups. </p> <p><a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported that three patients had an unexplained late occurrence of exanthema, one week after admission, which could have been due to acyclovir or to penicillin treatment preceding enrolment in the study. One patient in the acyclovir group suffered from diarrhoea and abdominal pain that resolved once acyclovir was withdrawn. No side effects were noticed in the placebo‐treated patients. Serum creatinine elevation of &gt; 10% above the normal level was found in three placebo and five acyclovir‐treated patients, all of which normalised within one month. </p> </section> </section> <section id="CD011487-sec-0085"> <h4 class="title">Secondary outcomes</h4> <section id="CD011487-sec-0086"> <h5 class="title">1. Duration of abnormal clinical examination (assessed by physician)</h5> <section id="CD011487-sec-0087"> <h6 class="title">1a. Duration of fever (&gt; 37.5° C)</h6> <p>Four of the seven included studies reported this outcome and one of these found a statistically significant difference between groups. </p> <p><a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> reported this as shift in change from baseline score at day 20. <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> also reported a dichotomous outcome: number of patients in each treatment group with fever at day 10. There was no statistically significant difference between the two groups in either of these studies. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported this as a continuous outcome: number of days. <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> found that there was a small statistically significant reduction in this in favour of the antiviral group (median number of days four versus six in the placebo group), whereas <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> found that there was no statistically significant difference between the two groups. </p> </section> <section id="CD011487-sec-0088"> <h6 class="title">1b. Duration of pharyngitis</h6> <p>Five of the seven included studies reported this outcome with one of these studies finding a significant effect in favour of antiviral treatment. </p> <p>Original data obtained from the lead author of the <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> study showed a statistically significant difference between the two groups for this outcome. Duration of pharyngitis in the treatment group was a mean of six days versus 12 in the placebo group. </p> <p><a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> reported the presence of sore throat for the two groups at different time points: day 1, 6, 10, and 15 (there was missing data on day 15) with no statistically significant difference between the groups at any of these time points. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported this as a continuous outcome: number of days. Both reported no statistically significant difference between the two groups. </p> <p><a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> reported a dichotomous outcome: number of patients in each treatment group with severe pharyngitis at day 10 with no statistically significant difference between the two groups. </p> <p>Pooling the results from <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a>, <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> indicated no statistically significant difference between groups (mean difference (MD) of one day fewer in the treatment group (95% CI ‐5.68 to 2.92, 117 participants)) (<a href="./references#CD011487-fig-0008" title="">Analysis 1.5</a>) </p> </section> <section id="CD011487-sec-0089"> <h6 class="title">1c. Duration of lymphadenopathy</h6> <p>Three of the seven included studies reported this outcome and one reported a statistically significant improvement in the anti‐viral treatment group. </p> <p>Original data obtained from the lead author of the <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> study showed that there was a statistically significant difference between the two groups for this outcome. Duration of lymphadenopathy in the treatment group was a mean of 11 days versus 20 in the placebo group. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported this as a continuous outcome: number of days. <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> found no statistically significant difference between the two groups. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported this outcome for three patients in the treatment group who were also administered steroids. It was not reported for the rest of the treatment group, or the placebo group. </p> <p>When the results of <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> were pooled, there was a mean reduction in number of days of nine (95% CI ‐11.75 to ‐6.14, 61 participants) (<a href="./references#CD011487-fig-0009" title="">Analysis 1.6</a>) in favour of the treatment group. The study <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> was weighted more than 99% in this analysis as the results for mean and SD in <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> were so large (the original median and range from <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> were converted to mean and SD using the method by <a href="./references#CD011487-bbs2-0039" title="HozoS P , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 20 April 2005;5:13. ">Hozo 2005</a>, already mentioned above). </p> </section> <section id="CD011487-sec-0090"> <h6 class="title">1d. Duration of splenomegaly</h6> <p>Two of the seven included studies reported this as a continuous outcome: number of days with no statistically significant difference between the two groups (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>). See <a href="./references#CD011487-fig-0010" title="">Analysis 1.7</a>. </p> </section> <section id="CD011487-sec-0091"> <h6 class="title">1e. Duration of hepatomegaly</h6> <p>Two of the seven included studies reported this as a continuous outcome: number of days with no statistically significant difference between the two groups (<a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a>; <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>). See <a href="./references#CD011487-fig-0011" title="">Analysis 1.8</a>. </p> </section> </section> <section id="CD011487-sec-0092"> <h5 class="title">2. Development of complications of infectious mononucleosis (IM)</h5> <p>Three of the seven included studies reported this outcome. We had planned to examine chronic fatigue (fatigue present for ≥ six months) as one of the specific complications of IM. Hoowever, this was not reported in the included studies. </p> <p>In <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a>, a 24‐year‐old participant who was in the treatment arm developed acute pancreatitis on the 10th study day. The authors considered that this was more likely to be a complication of IM rather than an adverse drug event. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> reported that one patient in the treatment group had to be tracheotomised, and acquired a transient, bilateral hypoglossal nerve palsy. One patient from the placebo group was operated on 12 days after admission because of abdominal pain with a surgical diagnosis of pseudo appendicitis, and another patient in the placebo group suffered from hepatitis with mild icterus persisting for seven months, where no other aetiologic agent could be demonstrated. During the six‐month follow‐up, a total of 12 cases of upper respiratory tract infection or tonsillitis were noted. Ten of the 12 were diagnosed as bacterial complications, and were evenly distributed in the two groups. </p> <p><a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported that there were three patients in the antiviral treatment group with over‐whelming clinical symptoms;two of the patients had severe upper respiratory obstruction which responded to combined steroid‐acyclovir therapy, the third patient developed disseminated intravascular coagulopathy, and had a fever of three weeks’ duration along with hepatitis and pancytopenia, despite effective inhibition of oropharyngeal EBV production during treatment. </p> <p><a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> stated 'no patients developed thrombocytopenia or anaemia during the study period'. </p> </section> <section id="CD011487-sec-0093"> <h5 class="title">3. Viral shedding</h5> <p>All of the studies except for <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> reported this outcome in some way. All reported similar techniques for detection of the Epstein‐Barr virus (EBV) oropharyngeal shedding. </p> <p><a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> reported inadequate sampling handling, but reported the percentage of patients who were culture positive at days zero and 10.The study reported that the differences between the groups were not statistically significant. It was unclear how many patients in each group these percentages were based on. </p> <p><a href="./references#CD011487-bbs2-0004" title="BalfourHHJr . Controlled trial of valacyclovir in infectious mononucleosis. Clinicaltrials.gov Last Updated: October 26, 2011. BalfourHHJr , HokansonKM , SchachererRM , FietzerCM , SchmelingDO , HolmanCJ , et al. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology2007;39:16‐21. ">Balfour 2007b</a> reported the quantity of EBV DNA in oral wash cells and supernatant at certain time points but this was only represented graphically and we were unable to extrapolate from this graph or obtain original data. </p> <p><a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> reported the number of patients with ≥2log₁₀ decrease in EBV copies/mL in oral cells, supernatant and whole blood at the end of treatment. Of these, only the data for supernatant showed a statistically significant result in favour of the antiviral, with a risk of 7.27 (95% CI 1.09 to 48.35). It also reported the median log₁₀ copies EBV/mL of the oral supernatant and oral cells at certain time points but this was only represented graphically and we were unable to extrapolate from this graph or obtain original data. </p> <p><a href="./references#CD011487-bbs2-0005" title="PaganoJS , SixbeyJW , LinJC . Acyclovir and Epstein‐Barr virus infection. Journal of Antimicrobial Chemotherapy1983;12(Suppl B):113‐21. ">Pagano 1983</a> reported this as a dichotomous outcome: oropharyngeal excretion of EBV at certain time points but there are a lot of missing data here making it difficult to interpret the findings. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> reported the proportion of oropharyngeal EBV shedders in treatment versus placebo groups at certain time points and found a statistically significant result on days four and seven, which was not sustained at days 28 and 180 after treatment was stopped. </p> <p><a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported the proportion of oropharyngeal EBV shedders in treatment versus placebo groups at certain time points and found a statistically significant during antiviral treatment, which was not sustained after treatment was stopped. </p> <p>Overall, each study that reported on viral shedding concluded that the antiviral drug suppressed viral shedding during treatment but the effect was not sustained when treatment was stopped. </p> </section> <section id="CD011487-sec-0094"> <h5 class="title">4. Patient‐reported outcome measures</h5> <p>Five of the seven studies reported patient‐reported outcome measures (PROMs)</p> <section id="CD011487-sec-0095"> <h6 class="title">4a. Health‐related quality of life (HRQoL)</h6> <p>Three of the included studies reported on HRQoL. <a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a> reported a 'sense of well being' in the abstract but did not report data for this outcome. </p> <p><a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> reported results for the SF12 composite score which was examined at day and one and day 28. There was no statistically significant difference between treatment and placebo groups. </p> <p><a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> reported a composite score ('feeling bad score', scored as absent (0), mild (1), moderate (2), or severe (3) from a scoring system developed by the authors) which found a non significant shift in change from baseline at day 20 between treatment and placebo groups. </p> </section> <section id="CD011487-sec-0096"> <h6 class="title">4b. Days missing from school of work</h6> <p>Four of the seven included studies reported on days missing from school or work with data available only for two of the studies, which found no difference between groups. </p> <p><a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> referred to a 'pattern of activities' and <a href="./references#CD011487-bbs2-0003" title="BalfourHHJr . Activity of valomaciclovir in infectious mononucleosis due to primary Epstein‐Barr virus infection (Mono6). Conference slides received by correspondence with the author. Further details obtained from Clinicaltrials.gov. 2007. ">Balfour 2007a</a> reported composite scores, but we were unable to obtain original data for these outcomes. </p> <p><a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> reported this as a continuous outcome: number of days with no statistically significant difference between the two groups. Pooling these two trial results did not give any statistically significant result either (MD ‐0.90, 95% CI ‐6.53 to 4.74, 87 participants) (<a href="./references#CD011487-fig-0014" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD011487-sec-0097"> <h5 class="title">5. Economic outcomes</h5> <p>Economic outcomes were not mentioned in any of the studies</p> </section> </section> <section id="CD011487-sec-0098"> <h4 class="title">Subgroups</h4> <p>We had planned to undertake subgroup analyses based on patient age, setting and placebo versus no treatment controls with sufficient data but this was not possible due to lack of appropriate data. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011487-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011487-sec-0099">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011487-sec-0141">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011487-sec-0099"></div> <section id="CD011487-sec-0100"> <h3 class="title" id="CD011487-sec-0100">Summary of main results</h3> <p>Results of this review need to be interpreted with caution as the quality of the evidence was graded as very low for all outcomes. There was a statistically significant improvement in the treatment group for only two of the 12 outcomes reported in included studies. Both of these outcomes were physician‐assessed outcomes, and may have limited clinical importance. </p> <p>Pooled results for 'time to clinical recovery as assessed by physician' indicated a mean reduction in the number of days of five days in the treatment group with wide confidence intervals (95% CI ‐8.04 to ‐1.08). However, it was unclear how this outcome was assessed in the studies reporting it. In one of these trials, three of the treatment group had steroids as a co‐intervention while none of the placebo group did, which may have affected the results also (<a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a>). Prospective studies report that clinical signs and symptoms start to resolve by one month (<a href="./references#CD011487-bbs2-0051" title="MacsweenKF , HigginsCD , McAulayKA , WilliamsH , HarrisonN , SwerdlowAJ , et al. Infectious mononucleosis in university students in the United Kingdom: evaluation of the clinical features and consequences of the disease. Clinical Infectious Diseases2010;50(5):699‐706. ">Macsween 2010</a>; <a href="./references#CD011487-bbs2-0053" title="ReaTD , RussoJE , KatonW , AshleyRL , BuchwaldDS . Prospective study of the natural history of infectious mononucleosis caused by Epstein‐Barr virus. Journal of the American Board of Family Practice / American Board of Family Practice2001;14:234‐42. ">Rea 2001</a>) and that fatigue may be persistent in approximately 10% of patients at six‐month follow‐up (<a href="./references#CD011487-bbs2-0029" title="BuchwaldDS , ReaTD , KatonWJ , RussoJE , AshleyRL . Acute infectious mononucleosis: characteristics of patients who report failure to recover. American Journal of Medicine2000;109:531‐7. ">Buchwald 2000</a>; <a href="./references#CD011487-bbs2-0059" title="WhitePD , ThomasJM , KangroHO , Bruce‐JonesWD , AmessJ , CrawfordDH , et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet2001;358(9297):1946‐54. ">White 2001</a>), so that a reduction in 'time to clinical recovery as assessed by physician' of five days in the treatment group may not be a clinically meaningful result. </p> <p>Results for the remaining four studies that examined our primary outcome in some way, all reported modest improvements in the treatment group, but these were mainly non statistically significant findings. </p> <p>Trial results for the outcome 'adverse events and side effects of medication' were reported narratively only in five studies. In some reports, authors were unsure whether an adverse event was related to medication or complication of disease. These results could not be pooled due to the potential for double counting results but overall, the majority of trials reporting this outcome did not find any significant difference between treatment and control groups. </p> <p>Results from <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> and <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> were pooled for the outcome 'duration of lymphadenopathy', with a mean reduction of nine days (95% CI ‐11.75 to ‐6.14) in favour of the treatment group. Within this meta‐analysis, <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> was weighted more than 99% as the standard deviations in <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> were so large. These two trials also reported very heterogenous results for this outcome with <a href="./references#CD011487-bbs2-0001" title="AnderssonJ , BrittonS , ErnbergI , AnderssonU , HenleW , SkoldenbergB , et al. Effect of acyclovir on infectious mononucleosis: a double‐blind, placebo‐controlled study. Journal of Infectious Diseases1986;153:283‐90. AnderssonJ , SkoldenbergB , ErnbergI , BrittonS , HenleW , AnderssonU . Acyclovir treatment in primary Epstein‐Barr virus infection. A double‐blind placebo‐controlled study. Scandinavian Journal of Infectious Diseases Supplement1985;47:107‐15. ErnbergI , AnderssonJ . Acyclovir efficiently inhibits oropharyngeal excretion of Epstein‐Barr virus in patients with acute infectious mononucleosis. Journal of General Virology1986;67:2267‐72. ">Andersson 1986</a> reporting lymphadenopathy of more than 1 cm diameter, whereas <a href="./references#CD011487-bbs2-0006" title="SimonMW , DeeterRG , ShahanB . The effect of valacyclovir and prednisolone in reducing symptoms of EBV illness in children: a double‐blind, placebo‐controlled study. International Pediatrics2003;18:164‐9. ">Simon 2003</a> reported the presence of lymphadenopathy as determined by physician assessment, but it is not clear what the criteria for reporting presence or absence was. </p> <p>The overall effect on viral shedding from the six studies that reported this outcome was that viral shedding was suppressed while on antiviral treatment, but this effect was not sustained when treatment was stopped. </p> <p>For the eight other outcomes reported in included studies there was no statistically significant effect of anti‐viral therapy in infectious mononucleosis (IM). </p> </section> <section id="CD011487-sec-0101"> <h3 class="title" id="CD011487-sec-0101">Overall completeness and applicability of evidence</h3> <p>Seven trials with a total of 333 participants met the inclusion criteria for this review. The trials were published between 1983 and 2007. In general, the number of participants in each trial was small; only one trial had more than 60 participants (<a href="./references#CD011487-bbs2-0007" title="van derHorstC , JoncasJ , AhronheimG , GustafsonN , SteinG , GurwithM , et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. Journal of Infectious Diseases1991;164:788‐92. ">van der Horst 1991</a>). Also, many of the effect sizes had wide confidence intervals (CIs) relating to the small sample sizes, reducing the precision of estimates. It is also possible that these studies were underpowered to detect potential differences in many of the secondary outcomes due to the small sample sizes. The trials were heterogenous in terms of setting (outpatient versus inpatient), severity of illness, antiviral treatment regimens (differences in antiviral used, dose and method of administration), age of participants (children versus young adults) outcomes assessed and reporting of data. Pooling of results was limited as a result of this heterogeneity, with results from three trials or less being pooled for any one outcome. We were unable to perform subgroup or sensitivity analyses for any of the outcomes. All included trials had inadequate outcome reporting. All included trials had either an unclear or high risk of bias. None of the trials reported on economic outcomes. These factors all limit the conclusions that can be drawn. </p> </section> <section id="CD011487-sec-0102"> <h3 class="title" id="CD011487-sec-0102">Quality of the evidence</h3> <p>The quality of the evidence was graded as very low for all outcomes which means that 'the true effect is likely to be substantially different from the estimate of effect' as per the GRADE Working Group grades of evidence. The evidence was downgraded in the domains of risk of bias due to the majority of studies having an unclear or high risk of bias; inconsistency due to wide variance of point estimates across studies, which may reflect differences in setting, type of antiviral, or route of medication administration; imprecision due to small sample sizes or wide CIs. </p> <p>Overall, the very low quality of the evidence means that we can place very little confidence in the results found. </p> </section> <section id="CD011487-sec-0103"> <h3 class="title" id="CD011487-sec-0103">Potential biases in the review process</h3> <p>We have attempted to limit bias in the review process. Though we used a thorough search strategy, we may not have identified all trials eligible for inclusion, especially unpublished trials. </p> </section> <section id="CD011487-sec-0104"> <h3 class="title" id="CD011487-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>Although our review includes two additional trials, the results are in agreement with the previous 1999 systematic review <a href="./references#CD011487-bbs2-0017" title="TorreD , TambiniR . Acyclovir for treatment of infectious mononucleosis: a meta‐analysis. Scandinavian Journal of Infectious Diseases1999;31:543‐7. ">Torre 1999</a>, concluding that there is not enough evidence to support the use of antiviral agents for IM. A recent narrative review article also concluded that treatment with acyclovir significantly decreased the rate of oropharyngeal viral shedding, but that there was no evidence to support its use in an acute setting (<a href="./references#CD011487-bbs2-0049" title="LennonP , CrottyM , FentonJE . Infectious mononucleosis. BMJ2015;350:NA. ">Lennon 2015</a>). </p> <p>Studies examining the effect of antivirals for other acute illnesses have generally found small improvements in outcomes in favour of antivirals but with the potential negative effects of medication costs, side effects and potential for antiviral resistance. A 2015 meta‐analysis published in the Lancet found that in adults with a laboratory diagnosis of influenza, oseltamivir accelerated time to clinical symptom alleviation, reduced the risk of antibiotic prescribing for lower respiratory tract infection and hospital admission for any cause (<a href="./references#CD011487-bbs2-0034" title="DobsonJ , WhitleyRJ , PocockS , MontoAS . Oseltamivir treatment for influenza in adults: a meta‐analysis of randomised controlled trials. Lancet2015;385:1729‐37. ">Dobson 2015</a>). There was no benefit conferred to patients who had symptoms of influenza‐like illness but not confirmed infection. A Cochrane review of acyclovir for varicella found that acyclovir was effective in reducing the number of days with fever and the maximum number of lesions but did not have an effect on complications or relief of itch among otherwise healthy children with chickenpox (<a href="./references#CD011487-bbs2-0045" title="KlassenTP , HartlingL , WiebeN , BelseckEM . Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD002980.pub3] ">Klassen 2005</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011487-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011487-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011487-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011487-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 1 Time to clinical recovery doctor judgement." data-id="CD011487-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 1 Time to clinical recovery doctor judgement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 2 Time to clinical recovery patient judgement." data-id="CD011487-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 2 Time to clinical recovery patient judgement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0006"> <p> <div class="table" id="CD011487-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersson 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Drug reactions.</i> Symptomless, transient elevation (15%) of serum creatinine and serum urea was noted in 2/15 ACV‐treated patients and none of the PLO treated patients." ''Thrombophlebitis occurred in four patients from each group. Skin rash was found in three ACV‐treated patients, all of whom had been given ampicillin before admission, compared with six patients in the placebo group , four of whom had been treated with the antibiotic before admission. No evidence of haematopoietic suppression was observed in the ACV‐treated patients." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Three patients had an unexplained late occurrence of exanthema, one week after admission which could have been due to acyclovir or to penicillin treatment preceding enrolment in the study. One patient in the acyclovir group suffered from diarrhoea and abdominal pain that disappeared once acyclovir was withdrawn. No side effects were noticed in the placebo‐treated patients. Serum creatinine elevation of &gt;10% above the normal level was found in three placebo and five acyclovir‐treated patients, who were all normalized within one month." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balfour 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were listed in a summary: Abdominal pain, headache, nausea, vomiting, rash, serious adverse event/complication. Of these; nausea was the only symptom where a statistically significant difference was observed between the two treatment groups with seven participants in the treatment group and one patient in the placebo group affected (P = 0.03). One serious adverse event was reported‐a case of pancreatitis ‐ "the case of pancreatitis was possibly drug‐related although it has been reported to be a complication of infectious mono." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balfour 2007b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No adverse events were observed. The only abnormal clinical chemistry results were elevations in the ALT and AST levels. The ALT and AST levels were elevated on enrollment in 7 of 10 valacyclovir subjects and in 8 of 10 control subjects. All ALT and AST levels returned to the normal range during the study period. The only other abnormal laboratory findings were mild leukocytosis (five subjects) and thrombocytopenia (four subjects) on enrollment. These abnormalities had all resolved when the subjects were tested again on the third study visit." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pagano 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simon 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van der Horst 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported that there was no difference between the two treatment groups in terms of side effects despite the large dose of acyclovir given </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 3 Adverse events and side effects. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0006">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011487-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 4 Duration of fever &gt; 37.5 degree C." data-id="CD011487-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 4 Duration of fever &gt; 37.5 degree C. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 5 Duration of pharyngitis." data-id="CD011487-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 5 Duration of pharyngitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 6 Duration of lymphadenopathy." data-id="CD011487-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 6 Duration of lymphadenopathy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 7 Duration of splenomegaly." data-id="CD011487-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 7 Duration of splenomegaly.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 8 Duration of hepatomegaly." data-id="CD011487-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 8 Duration of hepatomegaly.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011487-fig-0012"> <p> <div class="table" id="CD011487-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersson 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACV group: 'the most severely ill patient also had a mild infection with herpes zoster virus in the L2 region at admission. He had a tracheotomy because of an airway obstruction; this was followed by a transient, bilateral hypoglossal nerve palsy." </p> <p>Placebo group: "One patient was operated on on the 12<sup>th</sup> day after admission because of abdominal pain. Surgical diagnosis was pseudoappendicitis. One patient suffered from hepatitis that persisted for seven months with mild icterus. No other etiologic agent could be demonstrated." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were ‘three patients with over‐whelming clinical symptoms causing airway obstruction and/or disseminated intravascular coagulopathy". These 3 patients were treated with a combination of IV antiviral and steroids </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balfour 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A 24‐year‐old subject developed acute pancreatitis on the 10th study day and was hospitalized for 2 days for medical management. She was taken off clinical trial material and not re‐challenged.The blind was not broken. She is entirely well. When the code was broken, we learned that she was in the valomaciclovir arm. Thus, this SAE is possibly drug‐related, although I considered it more likely caused by EBV infection because pancreatitis has been reported to be a complication of infectious mononucleosis." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balfour 2007b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pagano 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simon 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van der Horst 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 9 Development of complications of infectious mononucleosis. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0012">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011487-fig-0013"> <p> <div class="table" id="CD011487-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersson 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall effect was that viral shedding was suppressed while on treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall effect was that viral shedding was suppressed while on treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balfour 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall effect was that viral shedding was suppressed while on treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balfour 2007b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall effect was that viral shedding was suppressed while on treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pagano 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall effect was that viral shedding was suppressed while on treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simon 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van der Horst 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall effect was that viral shedding was suppressed while on treatment but this was not sustained when treatment stopped </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 10 Viral shedding.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011487-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/urn:x-wiley:14651858:media:CD011487:CD011487-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_t/tCD011487-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals versus placebo/no treatment, Outcome 11 Days missing from school / work." data-id="CD011487-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Antivirals versus placebo/no treatment, Outcome 11 Days missing from school / work. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/media/CDSR/CD011487/image_n/nCD011487-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011487-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antivirals compared with placebo/no treatment for infectious mononucleosis (glandular fever)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antivirals compared with placebo/no treatment for infectious mononucleosis (glandular fever)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)<br/> <b>Setting:</b> hospitalised patients or outpatient setting<br/> <b>Intervention:</b> antivirals<br/> <b>Comparison:</b> placebo / no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antivirals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to clinical recovery doctor judgement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery doctor judgement was 20 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery doctor judgement in the intervention group was 5 days fewer (8.04 fewer to 1.08 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant reduction in favour of treatment group. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> had 3 patients in the treatment group who had a co‐administered steroid whereas none of the placebo group had this </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to clinical recovery patient judgement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery patient judgement was 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to clinical recovery patient judgement in the intervention group was 6 days fewer (26.23 fewer to 15.05 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference between groups. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> had 3 patients in the treatment group who had a co‐administered steroid whereas none of the placebo group had this </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events and side effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported narratively only in five studies. In some reports authors were unsure whether adverse event was related to medication or complication of disease </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of lymphadenopathy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of lymphadenopathy was 41 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of lymphadenopathy in the intervention group was 9 days fewer (11.75 fewer to 6.14 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference in favour of treatment group. One study weighted very heavily due to high variance in other study </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of complications of Infectious mononucleosis</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three studies reported complications narratively. There did not seem to be any difference in the incidence of complications between treatment and control groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral shedding</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall effect from all six studies was that viral shedding was suppressed while on antiviral treatment but this was not sustained when treatment stopped </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days missing from school / work</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days missing from school / work was 20 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days missing from school/work in the intervention group was 1 day fewer (6.53 fewer to 4.74 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference between groups. <a href="./references#CD011487-bbs2-0002" title="AnderssonJ , SkoldenbergB , HenleW , GieseckeJ , OrtqvistA , JulanderI , et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection1987;15(Suppl 1):14‐20. ">Andersson 1987</a> had 3 patients in the treatment group who had a co‐administered steroid whereas none of the placebo group had this </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for imprecision where sample size was very small (&lt; 200 participants) </p> <p><sup>2</sup> Downgraded one level for risk of bias due to the majority of studies included in this outcome having an unclear or high risk of bias </p> <p><sup>3</sup> Downgraded one level for indirectness as no study reported adverse events as a measurable outcome </p> <p><sup>4</sup> Downgraded one level for imprecision due to small sample sizes or wide confidence intervals for this outcome </p> <p><sup>5</sup> Downgraded one level for inconsistency due to wide variance of point estimates across studies and differences in setting, type of antiviral, or route of medication administration </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antivirals compared with placebo/no treatment for infectious mononucleosis (glandular fever)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/full#CD011487-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011487-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antivirals versus placebo/no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to clinical recovery doctor judgement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.56 [‐8.04, ‐1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to clinical recovery patient judgement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.59 [‐26.23, 15.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events and side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of fever &gt; 37.5 degree C <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.52 [‐6.66, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Duration of pharyngitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐5.68, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of lymphadenopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.94 [‐11.75, ‐6.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Duration of splenomegaly <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.68 [‐5.89, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of hepatomegaly <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [‐9.15, 18.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Development of complications of infectious mononucleosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Viral shedding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Days missing from school / work <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐6.53, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antivirals versus placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011487.pub2/references#CD011487-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011487.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011487-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011487-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011487-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD011487-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011487-note-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011487-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011487\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011487\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011487\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011487\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011487\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011487.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011487.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011487.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011487.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011487.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719780006"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011487.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719780009"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011487.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df11b58a5937f',t:'MTc0MDcxOTc4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 